Variant Resolution Through RNA Testing and Affected Tissue Analysis in the Neurofibromatoses

Read full text
Authors: Krista Sondergaard Schatz, Carolyn D. Applegate, Allan Joel Belzberg, Yunjia Chen, Carlos Guillermo Romo, Bronwyn Slobogean, Jaishri O'Neill Blakeley, Mazen M. Dimachkie
Cited by: 0

Abstract

Objectives: This series reports 3 unrelated individuals with features of neurofibromatosis type 1 (NF1) and/or schwannomatosis (SWN) in whom variants of uncertain significance (VUSs) were resolved through RNA testing and tissue analysis, highlighting the clinical impact of these tests. Methods: Each patient's genetic testing identified a VUS that could have explained their clinical presentation. Because diagnostic criteria were not met, we performed VUS resolution. For patient 1, we conducted tissue analysis and RNA-based Sanger sequencing. For patients 2 and 3, RNA-based Sanger sequencing was pursued. Results: c.377-13T>A VUS in patient 3 reclassified the variant as likely benign, ruling out diagnosis of germline Legius syndrome. Discussion: Because diagnostic criteria for NF1 and SWN include genetic testing, resolving VUSs in those who do not meet criteria is crucial for clinical care. In this article, we report 3 cases in which RNA testing and tissue analysis clarified pathogenicity of VUSs, thereby affecting clinical care, and in one case providing a definitive diagnosis.

Fields of Study & Subjects

Neurofibromatosis and Schwannoma Cases Genomics and Rare Diseases Hereditary Neurological Disorders

Publication details

Journal / source
Neurology Genetics
Volume
12
Issue
1
Pages
e200347–e200347
Publication date
1 February 2026
Language
EN